by Bonnell Foundation | Feb 13, 2018 | News
February 12, 2018 — Vertex announced that the U.S. FDA approved SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of...
by Bonnell Foundation | May 8, 2012 | Featured, News
Parents who have kids with the deltaF508 strain of cystic fibrosis will soon be able to breathe a little easier. Results from the clinical trials by Vertex Pharmaceutical’s have stocks climbing. The drug company climbed 55 percent to $58.12 at the close of the New...
by Bonnell Foundation | Jan 31, 2012 | Featured, News
The FDA has approved KalydecoTM (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), a rare, genetic disease. Kalydeco is approved for people with CF ages 6 and older who have at least one copy of the G551D mutation in the cystic...
